Bernd G. Jacob, MD; Werner O. Richter, MD; Peter Schwandt, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Genetically determined high concentrations of lipoprotein(a) [Lp(a)] have been strongly associated with premature cardiovascular disease (1), myocardial infarction (2), and cerebrovascular disease (3) in men. Until now, none of the classic hypolipidemic drugs has clearly been shown to influence this risk factor (4). There are controversial findings regarding the new class of HMG-CoA (3-hydroxy-3-methylglutaryl
coenzymeA) reductase inhibitors. Berg and Leren (5) reported unchanged serum Lp(a) concentrations in 30 patients with familial hypercholesterolemia treated with lovastatin, whereas Jürgens and colleagues (6) found an increased Lp(a) level during treatment with lovastatin in 8 patients. We therefore studied the effect
Jacob BG, Richter WO, Schwandt P. Lovastatin, Pravastatin, and Serum Lipoprotein(a). Ann Intern Med. 1990;112:713–714. doi: https://doi.org/10.7326/0003-4819-112-9-713_2
Download citation file:
Published: Ann Intern Med. 1990;112(9):713-714.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use